Low expression of microRNA‑30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein

Zhang,Jun; Wang,Xilong; Wang,Yangyun; Peng,Ruixian; Lin,Zhiyuan; Wang,Yang; Hu,Bo; Wang,Jifeng; Shi,Guowei

doi:10.3892/ol.2017.6163

Low expression of microRNA‑30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein

Authors:
- Jun Zhang
- Xilong Wang
- Yangyun Wang
- Ruixian Peng
- Zhiyuan Lin
- Yang Wang
- Bo Hu
- Jifeng Wang
- Guowei Shi
View Affiliations

Affiliations: Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, P.R. China
Published online on: May 12, 2017 https://doi.org/10.3892/ol.2017.6163
Pages: 363-368

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant microRNA expression is associated with tumor development. The present study aimed to elucidate the role of miR‑30c in the development of prostate cancer. Quantitative polymerase chain reaction was performed to compare miR‑30c expression in LNCaP, DU145, PC‑3 and RWPE‑1 cell lines. Lentivirus expressing miR‑30c was used to create stable overexpression cell lines to investigate the effects of miR‑30c overexpression on cell proliferation, migration and invasion, which were determined in the prostate cancer cell line PC‑3 by MTT, colony formation, wound healing and Transwell assays. Effects of miR‑30c on KRAS were examined by western blot analysis. miR‑30c expression was significantly lower (P<0.05) in the PC‑3 cell line compared with LNCaP, DU145 and RWPE‑1 cell lines. miR‑30c overexpression in PC‑3 inhibited tumor cell proliferation, migration and invasion in vitro. Furthermore, KRAS protein expression was downregulated in miR‑30c overexpression cell lines compared with the negative control (NC) group (P<0.05). The present results demonstrated that overexpression of miR‑30c inhibits prostate cancer cell line proliferation, migration and invasion, which was possibly caused by downregulation of KRAS protein by miR‑30c. The data implicate miR‑30c in the prognosis and treatment of prostate cancer.

View Figures

View References

1	Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, Wang G, Liu Z and Debré B: A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 16:4472–4477. 2009.PubMed/NCBI
2	Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM and Rebbeck TR: Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol. 15:4056–4064. 2008.PubMed/NCBI
3	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and Trends-An update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
4	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
5	Shi XB, Tepper CG and White RW deVere: Cancerous miRNAs and their regulation. Cell Cycle. 7:1529–1538. 2008. View Article : Google Scholar : PubMed/NCBI
6	Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68:6162–6170. 2008. View Article : Google Scholar : PubMed/NCBI
8	Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM and Yang J: A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 72:1443–1452. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C and Kaneva R: Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141 and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol. 34:189–200. 2015. View Article : Google Scholar : PubMed/NCBI
10	Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG and Mearini E: Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: Evaluation of potential diagnostic and prognostic role. Onco Targets Ther. 9:7545–7553. 2016. View Article : Google Scholar : PubMed/NCBI
11	Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G and Chartrand P: An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 282:2135–2143. 2007. View Article : Google Scholar : PubMed/NCBI
12	Dhar S, Kumar A, Rimando AM, Zhang X and Levenson AS: Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget. 6:27214–27226. 2015. View Article : Google Scholar : PubMed/NCBI
13	Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J and Jin Y: miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One. 5:e94292010. View Article : Google Scholar : PubMed/NCBI
14	Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, Li P, Niu X, Feng N, Zhang L, et al: MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate. 72:1171–1178. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB and Feng Q: MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol. 10:1742012. View Article : Google Scholar : PubMed/NCBI
16	Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F, Yan Y, Shi J and Hu Y: microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol Rep. 27:807–812. 2012.PubMed/NCBI
17	Zhong Z, Xia Y, Wang P, Liu B and Chen Y: Low expression of microRNA-30c promotes invasion by inducing epithelial mesenchymal transition in non-small cell lung cancer. Mol Med Rep. 10:2575–2579. 2014.PubMed/NCBI
18	Wu W, Zhang X, Liao Y, Zhang W, Cheng H, Deng Z, Shen J, Yuan Q, Zhang Y and Shen W: miR-30c negatively regulates the migration and invasion by targeting the immediate early response protein 2 in SMMC-7721 and HepG2 cells. Am J Cancer Res. 5:1435–1446. 2015.PubMed/NCBI
19	Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, De Weerd V, Sleijfer S, Martens JW and Foekens JA: MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 127:43–51. 2011. View Article : Google Scholar : PubMed/NCBI
20	Dobson JR, Taipaleenmäki H, Hu YJ, Hong D, van Wijnen AJ, Stein JL, Stein GS, Lian JB and Pratap J: hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. Cancer Cell Int. 14:732014. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM and Yang J: A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 72:1443–1452. 2012. View Article : Google Scholar : PubMed/NCBI
23	Tanic M, Yanowsky K, Rodriguez-Antona C, Andrés R, Márquez-Rodas I, Osorio A, Benitez J and Martinez-Delgado B: Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One. 7:e388472012. View Article : Google Scholar : PubMed/NCBI
24	Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26:293–300. 2007. View Article : Google Scholar : PubMed/NCBI
25	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
26	Yen MC, Shih YC, Hsu YL, Lin ES, Lin YS, Tsai EM, Ho YW, Hou MF and Kuo PL: Isolinderalactone enhances the inhibition of SOCS3 on STAT3 activity by decreasing miR-30c in breast cancer. Oncol Rep. 35:1356–1364. 2016.PubMed/NCBI